This was indicative of restoration of the immune response of the body, since normally the body will destroy pathogens when the immune system is functional by raising the temperature. Meanwhile, patent no. Unfortunately, it was a … This allows you to see what already exists, find out about technical aspects of your competitors’ work or spot trends in technology. The results of evaluations with candidiasis are tabulated in Table I under its disease category. Only the factual presentations of the article were utilized and the hypothesis of the authors was ignored. A method for increasing white blood cell counts in AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject. "Is The AIDS Virus A Science Fiction?" Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag.sub.4 O.sub.4). The onset of hepatomegaly was not spontaneous and varied from patient to patient, being in the range of 4-16 days. Current indicator diseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categories with the approximate percent distribution among AIDS patients: This invention concerns itself with the treatment and cure of candidiasis and wasting syndrome AIDS patients with Tetrasil*. We provide access to the largest single source of technical information in the world: our databases containing millions of patent documents. by Eric Claptop on Vimeo, the home for high quality videos and the people who… AIDS was suppressed, any permanent damage that had been done to the patients in the course of their succumbing to AIDS was not obviously cured or corrected by said crystal device treatment, rather said injury persisted and the patient was improved with respect to AIDS but still suffered from said permanent injury or impairment previously inflicted. All the other candidiasis syndrome people who previously did not respond to the indicated medications subsequently responded after the Tetrasil treatment. intravenously, into the bloodstream. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. Secondary menu. These two groups account for approximately one third of AIDS cases. Wasting syndrome 19% 3. © 2004-2021 FreePatentsOnline.com. Patent Buddy offers a free search of patents, inventors and current patent owners. The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag4O4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. United States Patent 5676977 Abstract: The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag 4 O 4 ) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. C. (101.3.degree. He was cured of his candidiasis, but unfortunately succumbed to his previous body damage. Further evidence of the recovery of the AIDS patients manifested itself 30 days after the initial injection when white blood cell counts were taken. FP. Search; Health / Coronavirus. Patents issued after 1975 can be easily searched by keyword using a number of free tools. He was cured of his candidiasis, but unfortunately succumbed to his previous body damage. However, she showed an increase in body temperature which was indicative of immune response. Claim: Patents Mean Deadly Diseases And Viruses Were Created Or Invented In A Lab The patient who died; first responded favorably to Diflucan, which previously gave no response. 24 February 2020. No. The facts presented in the article related to the method of selecting AIDS patients based on the five aforementioned etiological subgroups targeted by the CDC, and the evidence presented, that there is AIDS without HIV as well as with it so that an anti-viral agent in most instances will not necessarily restore the immunity system. Some, however, were in moderate (m) condition and others in poor (p) as designated in the Table. This application is a continuation-in-part of Gazette date. Tetrasil was administered at approximately 40 PPM of blood volume per patient as a suspension in a proprietary buffer solution (pH=6.5), supplied by Holipharm Corporation. 2014-04-10 15:56:22. Document number. US 65895596 A. . Field of Search: 424/618 514/495 AIDS CURE U.S. Patent #5676977-THIS VIDEO IS BEING CENSORED!!! Despite hepatomegaly, there was no interference with liver function. So, then when you take that bone-chilling information into account, and Google the number above (5676977), you find that it leads you to the PATENT for the cure for AIDS which was filed in 1994. All patients evaluated were terminal. Classification Viewer ; Patents. The female patient, whose condition improved from poor and terminal to be among the living, showed a decrease in the WBC. Accordingly, the tetrasilver tetroxide device performed in concert with and in full conformity with the ultimate objects of this invention. It should, of course, be recognized that the accompanying examples illustrate preferred embodiments of the present invention and are not intended as a means of defining the limits and scope of the present invention. The results of this test program comprise Example 5 of U.S. Pat. Legal code. Associated with AIDS (p. Tetrasil was administered at approximately 40 PPM of blood volume per patient as a suspension in a proprietary buffer solution (pH=6.5), supplied by Holipharm Corporation. This invention relates to a molecular scale device not only capable of destroying the AIDS virus, but of purging the human bloodstream of pathogens and restoring immunity to AIDS patients of the candidiasis and wasting syndrome categories. A single injection is all that is required under these conditions. Another object of this invention is to destroy ISM in humans manifesting AIDS diseases of said AIDS etiological subgroups irrespective as to whether said ISM was HIV induced, since it is known that humans may manifest AIDS and still be HIV negative, and thus restore the immune system in said humans. The initial evaluations entailed experimenting with various silver moieties cited in applicant's aforementioned patent, concentrations, non-reactive buffers and modes of administration. . & Terms of Use. The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Only one facility in the State of Israel is licensed for these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is affiliated with the Hebrew University-Hadassah Medical School where said evaluations were done. By that time all the AIDS patients had been released from the clinic and allowed to return home. Another object of this invention is to destroy ISM in humans manifesting AIDS diseases of said AIDS etiological subgroups irrespective as to whether said ISM was HIV induced, since it is known that humans may manifest AIDS and still be HIV negative, and thus restore the immune system in said humans. They are shown in Table I under the WBC column, which gives the initial and final WBC. The subject of the patent is “tetrasilver tetroxide”, or Ag4O4, a “diamagnetic semiconducting molecular crystal… utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans.” ISM suppression appears to be more critical than the destruction of HIV. This invention relates to a molecular scale device not only capable of destroying the AIDS virus, but of purging the human bloodstream of pathogens and restoring immunity to AIDS patients of the candidiasis and wasting syndrome categories. US 5676977 A 169-391-350-626-637 Summary. The results of evaluations with candidiasis are tabulated in Table I under its disease category. Associated with AIDS (p. US 5676977 A. After about 18 months of judicious efforts and initial failures, success was finally achieved in destroying the MAIDS virus in C57BL mice with a single intravenous injection. Method Of Curing Aids With Tetrasilver Tetroxide Molecular Crystal Devices. The I and F designations refer to initial and final values as shown. 7 Digits) Example: 2172863 or 2,172,863 Version number: 3.1.22. Accordingly, humans injected in this manner, upon being inspected after three weeks or more had elapsed and compared with similar humans that had been given placebos, were completely cured of AIDS. This concentration is slightly over double of the optimum concentration recommended in applicant's aforementioned U.S. patent for the destruction of the human AIDS virus in vitro. The results of this test program comprise Example 5 of U.S. Pat. In the mid-1990s, the US patent office approved US 5676977 A: “Method of curing AIDS with tetrasilver tetroxide molecular crystal devices.”. The patients two weeks prior to inoculation were removed from their AZT, AIDS therapy. Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag4 O4). As this invention may be embodied in several forms without departing from the spirit or essential characteristics thereof, the present embodiments are therefore illustrative and not restrictive, since the scope of the invention is defined by the appended claims rather than by the description preceding them, and all changes that fall within the metes and bounds of the claims or that form their functional as well as conjointly cooperative equivalents, are therefore intended to be embraced by these claims. This concentration is slightly over double of the optimum concentration recommended in applicant's aforementioned U.S. patent for the destruction of the human AIDS virus in vitro. Patents may be searched in the USPTO Patent Full-Text and Image Database (PatFT). 2007. from VideoGoogle Website Dr. Boyd Graves discusses the origin of AIDS as well as the United States' patented cure, all based on official government documentation. This is "AIDS CURE U.S. Patent #5676977-THIS VIDEO IS BEING CENSORED!!!" Another object of the invention is to provide for immunity restoration in said AIDS afflicted humans through a single injection. The initial evaluations entailed experimenting with various silver moieties cited in applicant's aforementioned patent, concentrations, non-reactive buffers and modes of administration. Find out if your invention is unique or if other inventors have filed patent applications that are considered to be prior art. Accordingly, the tetrasilver tetroxide device performed in concert with and in full conformity with the ultimate objects of this invention. Molecular crystal redox device for pharmaceuticals, Molecular crystal device for pharmaceuticals. See Answer. The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Evaluations with Tetrasil were conducted on AIDS patients at Lucha Contra el Sida, Comayaguela, Honduras. WBC indicates white cell blood count. 5,336,499. & Terms of Use. The test results indicate that one cannot rely on a single factor to indicate the demise of AIDS. ISM suppression appears to be more critical than the destruction of HIV. Its made out of silver: US Patent 5,676,977 AIDS Cure. Asked by Wiki User. Other details concerning the structure of the crystal and its mechanism against pathogens, the AIDS virus and ISM would analogously hold here, and have already been further elucidated in said patent. Encouraged by these evaluations and successes, applicant obtained permission to evaluate the crystals in vitro against murine acquired immune deficiency syndrome (MAIDS). After success with mice, the inventor was able to test the efficacy of said devices on two select etiological groups of terminal AIDS patients in a clinic in Tegucigalpa, Honduras, Central America. Dec 1, 2009. All candidiasis patients showed a dramatic increase in their white blood cell counts, indicative of the restoration of their immunity systems. The I and F designations refer to initial and final values as shown. Enter the patent numbers you are searching for in the box below. Another object of this invention is to destroy the AIDS virus when present in the systems of said AIDS afflicted humans. This was an unfortunate consequence of the treatment which resulted in enlarged livers in all patients except the second one. Another object of this invention is to destroy the AIDS virus when present in the systems of said AIDS afflicted humans. for the latest updated information of the database, see the Currency of information area. The X generally appears at the end of the numbers hand-written on full-page patent images; however, in patent collections and for search purposes, the X is considered to be the patent type – analogous to the "D" of design patents – and appears at the beginning of the number. Here is the US Patent 5,242,820 that was derived from AIDS Patents. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function. US Patent 5,676,977 is the one time treatment for “curing ” the AIDS virus. Furthermore, said devices are capable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or not created by the AIDS virus (HIV); so as to restore the immune system. Thus an optimum of 40 PPM of the devices by weight of human blood was found to be sufficient to completely obliterate AIDS. Subsequent to the filing of the aforementioned patent, further testing revealed complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the fact that said devices were harmless when ingested and inhaled, being non-toxic. Because of the extremely minute size of a single molecule of this crystal, several million of these devices may be employed in concert to destroy a virus colony to purge a life support system of ISM and pathogens with the consumption of only parts per trillion of the crystal devices. Put the numbers in the search. Privacy Policy The present invention relates to the employment of molecular crystals as anti-AIDS devices, but more particularly to the molecular crystal semiconductor tetrasilver tetroxide Ag4 O4 which has two monovalent and two trivalent silver ions per molecule, and which through this structural configuration enables intermolecular electron transfer capable of killing viruses and binding them to the resulting silver entity so that a single intravenous injection will completely obliterate acquired immune deficiency syndrome (AIDS) in humans. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. chemical pharmaceutical poison silver(I,III) oxide (other names include TST Search Menu Main Menu. 2. As this invention may be embodied in several forms without departing from the spirit or essential characteristics thereof, the present embodiments are therefore illustrative and not restrictive, since the scope of the invention is defined by the appended claims rather than by the description preceding them, and all changes that fall within the metes and bounds of the claims or that form their functional as well as conjointly cooperative equivalents, are therefore intended to be embraced by these claims.